-
1
-
-
84936791837
-
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
-
Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015;373:123-35.
-
(2015)
N Engl J Med
, vol.373
, pp. 123-135
-
-
Brahmer, J.1
Reckamp, K.L.2
Baas, P.3
-
2
-
-
84911493241
-
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
-
Reck M, Popat S, Reinmuth N, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25 Suppl 3:iii27-39.
-
(2014)
Ann Oncol
, vol.25
, pp. iii27-iii39
-
-
Reck, M.1
Popat, S.2
Reinmuth, N.3
-
3
-
-
84931340760
-
Targeted therapy for non-small cell lung cancer: current standards and the promise of the future
-
Chan BA, Hughes BG. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res 2015;4:36-54.
-
(2015)
Transl Lung Cancer Res
, vol.4
, pp. 36-54
-
-
Chan, B.A.1
Hughes, B.G.2
-
4
-
-
69949162760
-
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
-
Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
-
(2009)
N Engl J Med
, vol.361
, pp. 947-957
-
-
Mok, T.S.1
Wu, Y.L.2
Thongprasert, S.3
-
5
-
-
84857502654
-
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
-
Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46.
-
(2012)
Lancet Oncol
, vol.13
, pp. 239-246
-
-
Rosell, R.1
Carcereny, E.2
Gervais, R.3
-
6
-
-
84918804764
-
First-line crizotinib versus chemotherapy in ALK-positive lung cancer
-
Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167-77.
-
(2014)
N Engl J Med
, vol.371
, pp. 2167-2177
-
-
Solomon, B.J.1
Mok, T.2
Kim, D.W.3
-
7
-
-
0028955388
-
Epidermal growth factor-related peptides and their receptors in human malignancies
-
Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
-
(1995)
Crit Rev Oncol Hematol
, vol.19
, pp. 183-232
-
-
Salomon, D.S.1
Brandt, R.2
Ciardiello, F.3
-
8
-
-
33745002702
-
An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor
-
Zhang X, Gureasko J, Shen K, et al. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006;125:1137-49.
-
(2006)
Cell
, vol.125
, pp. 1137-1149
-
-
Zhang, X.1
Gureasko, J.2
Shen, K.3
-
9
-
-
20044364940
-
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
-
Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-46.
-
(2005)
J Natl Cancer Inst
, vol.97
, pp. 339-346
-
-
Shigematsu, H.1
Lin, L.2
Takahashi, T.3
-
10
-
-
84921892043
-
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
-
Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 2015;16:141-51.
-
(2015)
Lancet Oncol
, vol.16
, pp. 141-151
-
-
Yang, J.C.1
Wu, Y.L.2
Schuler, M.3
-
11
-
-
84896719958
-
Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer
-
Vanderlaan PA, Yamaguchi N, Folch E, et al. Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer. Lung Cancer 2014;84:39-44.
-
(2014)
Lung Cancer
, vol.84
, pp. 39-44
-
-
Vanderlaan, P.A.1
Yamaguchi, N.2
Folch, E.3
-
12
-
-
84880312534
-
Analysis of the effect of various decalcification agents on the quantity and quality of nucleic acid (DNA and RNA) recovered from bone biopsies
-
Singh VM, Salunga RC, Huang VJ, et al. Analysis of the effect of various decalcification agents on the quantity and quality of nucleic acid (DNA and RNA) recovered from bone biopsies. Ann Diagn Pathol 2013;17:322-6.
-
(2013)
Ann Diagn Pathol
, vol.17
, pp. 322-326
-
-
Singh, V.M.1
Salunga, R.C.2
Huang, V.J.3
-
13
-
-
84898542288
-
Liquid biopsies: genotyping circulating tumor DNA
-
Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 2014;32:579-86.
-
(2014)
J Clin Oncol
, vol.32
, pp. 579-586
-
-
Diaz, L.A.1
Bardelli, A.2
-
14
-
-
84863393080
-
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing
-
Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.
-
(2012)
N Engl J Med
, vol.366
, pp. 883-892
-
-
Gerlinger, M.1
Rowan, A.J.2
Horswell, S.3
-
16
-
-
84871756952
-
Use of research biopsies in clinical trials: are risks and benefits adequately discussed?
-
Overman MJ, Modak J, Kopetz S, et al. Use of research biopsies in clinical trials: are risks and benefits adequately discussed? J Clin Oncol 2013;31:17-22.
-
(2013)
J Clin Oncol
, vol.31
, pp. 17-22
-
-
Overman, M.J.1
Modak, J.2
Kopetz, S.3
-
17
-
-
84928739294
-
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer
-
Jänne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015;372:1689-99.
-
(2015)
N Engl J Med
, vol.372
, pp. 1689-1699
-
-
Jänne, P.A.1
Yang, J.C.2
Kim, D.W.3
-
18
-
-
84928746232
-
Rociletinib in EGFR-mutated non-small-cell lung cancer
-
Sequist LV, Soria JC, Goldman JW, et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med 2015;372:1700-9.
-
(2015)
N Engl J Med
, vol.372
, pp. 1700-1709
-
-
Sequist, L.V.1
Soria, J.C.2
Goldman, J.W.3
-
19
-
-
0026707677
-
CEA serum levels in non-neoplastic disease
-
Ruibal Morell A. CEA serum levels in non-neoplastic disease. Int J Biol Markers 1992;7:160-6.
-
(1992)
Int J Biol Markers
, vol.7
, pp. 160-166
-
-
Ruibal Morell, A.1
-
20
-
-
85015462482
-
Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients
-
Ilie M, Hofman V, Long E, et al. Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine? Ann Transl Med 2014;2:107.
-
(2014)
What is the best blood substrate for personalized medicine? Ann Transl Med
, vol.2
, pp. 107
-
-
Ilie, M.1
Hofman, V.2
Long, E.3
-
21
-
-
84896371874
-
Detection of circulating tumor DNA in early- and late-stage human malignancies
-
Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014;6:224ra24.
-
(2014)
Sci Transl Med
, vol.6
-
-
Bettegowda, C.1
Sausen, M.2
Leary, R.J.3
-
22
-
-
84957852098
-
Les acides nucléiques du plasma sanguin chez l'homme
-
Mandel P, Metais P. Les acides nucléiques du plasma sanguin chez l'homme. C R Seances Soc Biol Fil 1948;142:241-3.
-
(1948)
C R Seances Soc Biol Fil
, vol.142
, pp. 241-243
-
-
Mandel, P.1
Metais, P.2
-
23
-
-
84859813987
-
Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib
-
Punnoose EA, Atwal S, Liu W, et al. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res 2012;18:2391-401.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 2391-2401
-
-
Punnoose, E.A.1
Atwal, S.2
Liu, W.3
-
24
-
-
41649114743
-
Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer
-
Frattini M, Gallino G, Signoroni S, et al. Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer. Cancer Lett 2008;263:170-81.
-
(2008)
Cancer Lett
, vol.263
, pp. 170-181
-
-
Frattini, M.1
Gallino, G.2
Signoroni, S.3
-
25
-
-
84875520648
-
Analysis of circulating tumor DNA to monitor metastatic breast cancer
-
Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013;368:1199-209.
-
(2013)
N Engl J Med
, vol.368
, pp. 1199-1209
-
-
Dawson, S.J.1
Tsui, D.W.2
Murtaza, M.3
-
26
-
-
63449103435
-
Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients
-
Yung TK, Chan KC, Mok TS, et al. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res 2009;15:2076-84.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 2076-2084
-
-
Yung, T.K.1
Chan, K.C.2
Mok, T.S.3
-
27
-
-
84861746437
-
Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA
-
Forshew T, Murtaza M, Parkinson C, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 2012;4:136ra68.
-
(2012)
Sci Transl Med
, vol.4
-
-
Forshew, T.1
Murtaza, M.2
Parkinson, C.3
-
28
-
-
79960975050
-
Circulating cell-free DNA in plasma of never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy
-
Lee YJ, Yoon KA, Han JY, et al. Circulating cell-free DNA in plasma of never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy. Clin Cancer Res 2011;17:5179-87.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 5179-5187
-
-
Lee, Y.J.1
Yoon, K.A.2
Han, J.Y.3
-
29
-
-
84862999938
-
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
-
Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012;486:532-6.
-
(2012)
Nature
, vol.486
, pp. 532-536
-
-
Misale, S.1
Yaeger, R.2
Hobor, S.3
-
30
-
-
84865782536
-
Potential clinical significance of plasma-based KRAS mutation analysis using the COLD-PCR/TaqMan(®) -MGB probe genotyping method
-
Liu P, Liang H, Xue L, et al. Potential clinical significance of plasma-based KRAS mutation analysis using the COLD-PCR/TaqMan(®) -MGB probe genotyping method. Exp Ther Med 2012;4:109-112.
-
(2012)
Exp Ther Med
, vol.4
, pp. 109-112
-
-
Liu, P.1
Liang, H.2
Xue, L.3
-
31
-
-
43249116705
-
Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing
-
Li J, Wang L, Mamon H, et al. Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nat Med 2008;14:579-84.
-
(2008)
Nat Med
, vol.14
, pp. 579-584
-
-
Li, J.1
Wang, L.2
Mamon, H.3
-
32
-
-
33644799347
-
Determination of allele frequency in pooled DNA: comparison of three PCR-based methods
-
Wilkening S, Hemminki K, Thirumaran RK, et al. Determination of allele frequency in pooled DNA: comparison of three PCR-based methods. Biotechniques 2005;39:853-8.
-
(2005)
Biotechniques
, vol.39
, pp. 853-858
-
-
Wilkening, S.1
Hemminki, K.2
Thirumaran, R.K.3
-
33
-
-
84655167222
-
Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer
-
Goto K, Ichinose Y, Ohe Y, et al. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. J Thorac Oncol 2012;7:115-21.
-
(2012)
J Thorac Oncol
, vol.7
, pp. 115-121
-
-
Goto, K.1
Ichinose, Y.2
Ohe, Y.3
-
34
-
-
81255175501
-
High-throughput droplet digital PCR system for absolute quantitation of DNA copy number
-
Hindson BJ, Ness KD, Masquelier DA, et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem 2011;83:8604-10.
-
(2011)
Anal Chem
, vol.83
, pp. 8604-8610
-
-
Hindson, B.J.1
Ness, K.D.2
Masquelier, D.A.3
-
35
-
-
28044468634
-
Detection and quantification of mutations in the plasma of patients with colorectal tumors
-
Diehl F, Li M, Dressman D, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A 2005;102:16368-73.
-
(2005)
Proc Natl Acad Sci U S A
, vol.102
, pp. 16368-16373
-
-
Diehl, F.1
Li, M.2
Dressman, D.3
-
36
-
-
84877579861
-
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
-
Murtaza M, Dawson SJ, Tsui DW, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013;497:108-12.
-
(2013)
Nature
, vol.497
, pp. 108-112
-
-
Murtaza, M.1
Dawson, S.J.2
Tsui, D.W.3
-
37
-
-
33746100318
-
Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer
-
Kimura H, Kasahara K, Kawaishi M, et al. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res 2006;12:3915-21.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 3915-3921
-
-
Kimura, H.1
Kasahara, K.2
Kawaishi, M.3
-
38
-
-
34548593298
-
Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA)
-
Kimura H, Suminoe M, Kasahara K, et al. Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br J Cancer 2007;97:778-84.
-
(2007)
Br J Cancer
, vol.97
, pp. 778-784
-
-
Kimura, H.1
Suminoe, M.2
Kasahara, K.3
-
39
-
-
84874114196
-
Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients
-
Zhao X, Han RB, Zhao J, et al. Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients. Respiration 2013;85:119-25.
-
(2013)
Respiration
, vol.85
, pp. 119-125
-
-
Zhao, X.1
Han, R.B.2
Zhao, J.3
-
40
-
-
84938289394
-
Dynamic plasma EGFR mutation status as a predictor of EGFR-TKI efficacy in patients with EGFR-mutant lung adenocarcinoma
-
Tseng JS, Yang TY, Tsai CR, et al. Dynamic plasma EGFR mutation status as a predictor of EGFR-TKI efficacy in patients with EGFR-mutant lung adenocarcinoma. J Thorac Oncol 2015;10:603-10.
-
(2015)
J Thorac Oncol
, vol.10
, pp. 603-610
-
-
Tseng, J.S.1
Yang, T.Y.2
Tsai, C.R.3
-
41
-
-
84899956118
-
Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays
-
Weber B, Meldgaard P, Hager H, et al. Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays. BMC Cancer 2014;14:294.
-
(2014)
BMC Cancer
, vol.14
, pp. 294
-
-
Weber, B.1
Meldgaard, P.2
Hager, H.3
-
42
-
-
84906250256
-
Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status
-
Douillard JY, Ostoros G, Cobo M, et al. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol 2014;9:1345-53.
-
(2014)
J Thorac Oncol
, vol.9
, pp. 1345-1353
-
-
Douillard, J.Y.1
Ostoros, G.2
Cobo, M.3
-
43
-
-
84938399710
-
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
-
Mok T, Wu YL, Lee JS, et al. Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy. Clin Cancer Res 2015;21:3196-203.
-
(2015)
Clin Cancer Res
, vol.21
, pp. 3196-3203
-
-
Mok, T.1
Wu, Y.L.2
Lee, J.S.3
-
44
-
-
84923059431
-
Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis
-
Luo J, Shen L, Zheng D. Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis. Sci Rep 2014;4:6269.
-
(2014)
Sci Rep
, vol.4
, pp. 6269
-
-
Luo, J.1
Shen, L.2
Zheng, D.3
-
45
-
-
84921032852
-
Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis
-
Qiu M, Wang J, Xu Y, et al. Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2015;24:206-12.
-
(2015)
Cancer Epidemiol Biomarkers Prev
, vol.24
, pp. 206-212
-
-
Qiu, M.1
Wang, J.2
Xu, Y.3
-
46
-
-
70349850471
-
Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer
-
He C, Liu M, Zhou C, et al. Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer. Int J Cancer 2009;125:2393-9.
-
(2009)
Int J Cancer
, vol.125
, pp. 2393-2399
-
-
He, C.1
Liu, M.2
Zhou, C.3
-
47
-
-
65249127504
-
Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer
-
Kuang Y, Rogers A, Yeap BY, et al. Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin Cancer Res 2009;15:2630-6.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 2630-2636
-
-
Kuang, Y.1
Rogers, A.2
Yeap, B.Y.3
-
48
-
-
66849091226
-
Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer
-
Bai H, Mao L, Wang HS, et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol 2009;27:2653-9.
-
(2009)
J Clin Oncol
, vol.27
, pp. 2653-2659
-
-
Bai, H.1
Mao, L.2
Wang, H.S.3
-
49
-
-
80053462384
-
Screening for activating EGFR mutations in surgically resected nonsmall cell lung cancer
-
Sriram KB, Tan ME, Savarimuthu SM, et al. Screening for activating EGFR mutations in surgically resected nonsmall cell lung cancer. Eur Respir J 2011;38:903-10.
-
(2011)
Eur Respir J
, vol.38
, pp. 903-910
-
-
Sriram, K.B.1
Tan, M.E.2
Savarimuthu, S.M.3
-
50
-
-
80052240913
-
Serum detection of epidermal growth factor receptor gene mutations using mutant-enriched sequencing in Chinese patients with advanced non-small cell lung cancer
-
Jiang B, Liu F, Yang L, et al. Serum detection of epidermal growth factor receptor gene mutations using mutant-enriched sequencing in Chinese patients with advanced non-small cell lung cancer. J Int Med Res 2011;39:1392-401.
-
(2011)
J Int Med Res
, vol.39
, pp. 1392-1401
-
-
Jiang, B.1
Liu, F.2
Yang, L.3
-
51
-
-
81855208762
-
Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas
-
Taniguchi K, Uchida J, Nishino K, et al. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res 2011;17:7808-15.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 7808-7815
-
-
Taniguchi, K.1
Uchida, J.2
Nishino, K.3
-
52
-
-
79957767374
-
Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors
-
Brevet M, Johnson ML, Azzoli CG, et al. Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors. Lung Cancer 2011;73:96-102.
-
(2011)
Lung Cancer
, vol.73
, pp. 96-102
-
-
Brevet, M.1
Johnson, M.L.2
Azzoli, C.G.3
-
53
-
-
84865697491
-
Application of a highly sensitive detection system for epidermal growth factor receptor mutations in plasma DNA
-
Nakamura T, Sueoka-Aragane N, Iwanaga K, et al. Application of a highly sensitive detection system for epidermal growth factor receptor mutations in plasma DNA. J Thorac Oncol 2012;7:1369-81.
-
(2012)
J Thorac Oncol
, vol.7
, pp. 1369-1381
-
-
Nakamura, T.1
Sueoka-Aragane, N.2
Iwanaga, K.3
-
54
-
-
84866437399
-
Direct serum and tissue assay for EGFR mutation in non-small cell lung cancer by high-resolution melting analysis
-
Hu C, Liu X, Chen Y, et al. Direct serum and tissue assay for EGFR mutation in non-small cell lung cancer by high-resolution melting analysis. Oncol Rep 2012;28:1815-21.
-
(2012)
Oncol Rep
, vol.28
, pp. 1815-1821
-
-
Hu, C.1
Liu, X.2
Chen, Y.3
-
55
-
-
84865712449
-
The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR-TKI
-
Huang Z, Wang ZJ, Bai H, et al. The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR-TKI. Thorac Cancer 2012;3:334-40.
-
(2012)
Thorac Cancer
, vol.3
, pp. 334-340
-
-
Huang, Z.1
Wang, Z.J.2
Bai, H.3
-
56
-
-
84887232098
-
Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib
-
Xu F, Wu J, Xue C, et al. Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib. Onco Targets Ther 2012;5:439-47.
-
(2012)
Onco Targets Ther
, vol.5
, pp. 439-447
-
-
Xu, F.1
Wu, J.2
Xue, C.3
-
57
-
-
84862893803
-
EGFR array: uses in the detection of plasma EGFR mutations in non-small cell lung cancer patients
-
Yam I, Lam DC, Chan K, et al. EGFR array: uses in the detection of plasma EGFR mutations in non-small cell lung cancer patients. J Thorac Oncol 2012;7:1131-40.
-
(2012)
J Thorac Oncol
, vol.7
, pp. 1131-1140
-
-
Yam, I.1
Lam, D.C.2
Chan, K.3
-
58
-
-
84892453399
-
High resolution melting analysis for epidermal growth factor receptor mutations in formalin-fixed paraffin-embedded tissue and plasma free DNA from non-small cell lung cancer patients
-
Jing CW, Wang Z, Cao HX, et al. High resolution melting analysis for epidermal growth factor receptor mutations in formalin-fixed paraffin-embedded tissue and plasma free DNA from non-small cell lung cancer patients. Asian Pac J Cancer Prev 2014;14:6619-23.
-
(2014)
Asian Pac J Cancer Prev
, vol.14
, pp. 6619-6623
-
-
Jing, C.W.1
Wang, Z.2
Cao, H.X.3
-
59
-
-
84892753732
-
The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies
-
Liu X, Lu Y, Zhu G, et al. The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies. J Clin Pathol 2013;66:1065-9.
-
(2013)
J Clin Pathol
, vol.66
, pp. 1065-1069
-
-
Liu, X.1
Lu, Y.2
Zhu, G.3
-
60
-
-
84876673062
-
A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma
-
Lv C, Ma Y, Feng Q, et al. A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma. World J Surg Oncol 2013;11:96.
-
(2013)
World J Surg Oncol
, vol.11
, pp. 96
-
-
Lv, C.1
Ma, Y.2
Feng, Q.3
-
61
-
-
84885980911
-
Comparison of EGFR signaling pathway somatic DNA mutations derived from peripheral blood and corresponding tumor tissue of patients with advanced non-small-cell lung cancer using liquidchip technology
-
Zhang H, Liu D, Li S, et al. Comparison of EGFR signaling pathway somatic DNA mutations derived from peripheral blood and corresponding tumor tissue of patients with advanced non-small-cell lung cancer using liquidchip technology. J Mol Diagn 2013;15:819-26.
-
(2013)
J Mol Diagn
, vol.15
, pp. 819-826
-
-
Zhang, H.1
Liu, D.2
Li, S.3
-
62
-
-
84872036190
-
Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)?
-
Kim ST, Sung JS, Jo UH, et al. Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)? Med Oncol 2013;30:328.
-
(2013)
Med Oncol
, vol.30
, pp. 328
-
-
Kim, S.T.1
Sung, J.S.2
Jo, U.H.3
-
63
-
-
84881137132
-
Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping
-
Kim HR, Lee SY, Hyun DS, et al. Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping. J Exp Clin Cancer Res 2013;32:50.
-
(2013)
J Exp Clin Cancer Res
, vol.32
, pp. 50
-
-
Kim, H.R.1
Lee, S.Y.2
Hyun, D.S.3
-
64
-
-
84903181938
-
Peripheral blood for epidermal growth factor receptor mutation detection in non-small cell lung cancer patients
-
Li X, Ren R, Ren S, et al. Peripheral blood for epidermal growth factor receptor mutation detection in non-small cell lung cancer patients. Transl Oncol 2014;7:341-8.
-
(2014)
Transl Oncol
, vol.7
, pp. 341-348
-
-
Li, X.1
Ren, R.2
Ren, S.3
-
65
-
-
84892880094
-
Clinical significance of pretreatment plasma biomarkers in advanced non-small cell lung cancer patients
-
Wang S, Han X, Hu X, et al. Clinical significance of pretreatment plasma biomarkers in advanced non-small cell lung cancer patients. Clin Chim Acta 2014;430:63-70.
-
(2014)
Clin Chim Acta
, vol.430
, pp. 63-70
-
-
Wang, S.1
Han, X.2
Hu, X.3
-
66
-
-
84865442609
-
Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer
-
Bai H, Wang Z, Chen K, et al. Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J Clin Oncol 2012;30:3077-83.
-
(2012)
J Clin Oncol
, vol.30
, pp. 3077-3083
-
-
Bai, H.1
Wang, Z.2
Chen, K.3
-
67
-
-
84942265943
-
Investigating the utility of circulating-free tumour-derived DNA (ctDNA) in plasma for the detection of epidermal growth factor receptor (EGFR) mutation status in european and japanese patients (PTS) with advanced non-small-cell lung cancer (ANSCLC): ASSESS study
-
Geneva, Switzerland
-
Reck M, Hagiwara K, Han B, et al. Investigating the utility of circulating-free tumour-derived DNA (ctDNA) in plasma for the detection of epidermal growth factor receptor (EGFR) mutation status in european and japanese patients (PTS) with advanced non-small-cell lung cancer (ANSCLC): ASSESS study. European Lung Cancer Conference, Geneva, Switzerland, 2015;abstr: 229.
-
(2015)
European Lung Cancer Conference
-
-
Reck, M.1
Hagiwara, K.2
Han, B.3
-
68
-
-
84960189012
-
Determining the prevalence of EGFR mutations in Asian and Russian patients (pts) with advanced non-small-cell lung cancer (aNSCLC) of adenocarcinoma (ADC) and non-ADC histology: IGNITE study
-
Geneva, Switzerland
-
Han B, Tjulandin S, Hagiwara K, et al. Determining the prevalence of EGFR mutations in Asian and Russian patients (pts) with advanced non-small-cell lung cancer (aNSCLC) of adenocarcinoma (ADC) and non-ADC histology: IGNITE study. European Lung Cancer Conference, Geneva, Switzerland, 2015;abstr: 233.
-
(2015)
European Lung Cancer Conference
-
-
Han, B.1
Tjulandin, S.2
Hagiwara, K.3
-
69
-
-
77954580523
-
Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors
-
Benesova L, Minarik M, Jancarikova D, et al. Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors. Anticancer Res 2010;30:1667-71.
-
(2010)
Anticancer Res
, vol.30
, pp. 1667-1671
-
-
Benesova, L.1
Minarik, M.2
Jancarikova, D.3
-
70
-
-
76749151984
-
Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer
-
Wang S, An T, Wang J, et al. Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer. Clin Cancer Res 2010;16:1324-30.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 1324-1330
-
-
Wang, S.1
An, T.2
Wang, J.3
-
71
-
-
84960189013
-
Association of KRAS mutations in cell-free circulating tumor DNA with occurrence of resistance to TKIs in NSCLC
-
Del Re M, Landi L, Tiseo M, et al. Association of KRAS mutations in cell-free circulating tumor DNA with occurrence of resistance to TKIs in NSCLC. J Clin Oncol 2014;32:5 suppl: abstr 11056.
-
(2014)
J Clin Oncol
, vol.32
, Issue.5
-
-
Del Re, M.1
Landi, L.2
Tiseo, M.3
-
72
-
-
79953118839
-
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
-
Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75ra26.
-
(2011)
Sci Transl Med
, vol.3
-
-
Sequist, L.V.1
Waltman, B.A.2
Dias-Santagata, D.3
-
73
-
-
84877100240
-
Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers
-
Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013;19:2240-7.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 2240-2247
-
-
Yu, H.A.1
Arcila, M.E.2
Rekhtman, N.3
-
74
-
-
84904756821
-
Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer
-
Sacher AG, Jänne PA, Oxnard GR. Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer. Cancer 2014;120:2289-98.
-
(2014)
Cancer
, vol.120
, pp. 2289-2298
-
-
Sacher, A.G.1
Jänne, P.A.2
Oxnard, G.R.3
-
75
-
-
13844317894
-
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
-
Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92.
-
(2005)
N Engl J Med
, vol.352
, pp. 786-792
-
-
Kobayashi, S.1
Boggon, T.J.2
Dayaram, T.3
-
76
-
-
18244371651
-
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
-
Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
-
(2005)
PLoS Med
, vol.2
, pp. e73
-
-
Pao, W.1
Miller, V.A.2
Politi, K.A.3
-
77
-
-
40049099220
-
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
-
Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 2008;105:2070-5.
-
(2008)
Proc Natl Acad Sci U S A
, vol.105
, pp. 2070-2075
-
-
Yun, C.H.1
Mengwasser, K.E.2
Toms, A.V.3
-
78
-
-
79952711946
-
Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation
-
Oxnard GR, Arcila ME, Sima CS, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 2011;17:1616-22.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 1616-1622
-
-
Oxnard, G.R.1
Arcila, M.E.2
Sima, C.S.3
-
79
-
-
84960090586
-
Association between clinical outcome of first EGFR-TKIs and T790M mutation in NSCLC patients harboring EGFR mutation with acquired resistance to EGFR-TKIs
-
Oya Y, Yoshida T, Tanaka K, et al. Association between clinical outcome of first EGFR-TKIs and T790M mutation in NSCLC patients harboring EGFR mutation with acquired resistance to EGFR-TKIs. J Clin Oncol 2015;33:suppl; abstr e19123.
-
(2015)
J Clin Oncol
, vol.33
-
-
Oya, Y.1
Yoshida, T.2
Tanaka, K.3
-
80
-
-
84960189014
-
Association of plasma EGFR T790M ctDNA status with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance
-
Zheng Di, Ye X, Zhang M, et al. Association of plasma EGFR T790M ctDNA status with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance. J Clin Oncol 2015;33:suppl; abstr 8080.
-
(2015)
J Clin Oncol
, vol.33
-
-
Di, Z.1
Ye, X.2
Zhang, M.3
-
81
-
-
84896539307
-
Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA
-
Oxnard GR, Paweletz CP, Kuang Y, et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res 2014;20:1698-705.
-
(2014)
Clin Cancer Res
, vol.20
, pp. 1698-1705
-
-
Oxnard, G.R.1
Paweletz, C.P.2
Kuang, Y.3
-
82
-
-
84918789657
-
Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib
-
Sorensen BS, Wu L, Wei W, et al. Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib. Cancer 2014;120:3896-901.
-
(2014)
Cancer
, vol.120
, pp. 3896-3901
-
-
Sorensen, B.S.1
Wu, L.2
Wei, W.3
-
83
-
-
84942521073
-
Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of non-small cell lung cancer patients
-
Marchetti A, Palma JF, Felicioni L, et al. Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of non-small cell lung cancer patients. J Clin Oncol 2015;33:suppl; abstr 8079.
-
(2015)
J Clin Oncol
, vol.33
-
-
Marchetti, A.1
Palma, J.F.2
Felicioni, L.3
-
84
-
-
84960189016
-
Dynamic serial monitoring of EGFR mutations in plasma DNA samples in EGFR mutant NSCLC patients treated with EGFR TKI
-
Ahn MJ, Lee JY, Lim SH, et al. Dynamic serial monitoring of EGFR mutations in plasma DNA samples in EGFR mutant NSCLC patients treated with EGFR TKI. J Clin Oncol 2015;33:suppl; abstr 8078.
-
(2015)
J Clin Oncol
, vol.33
-
-
Ahn, M.J.1
Lee, J.Y.2
Lim, S.H.3
-
85
-
-
84914703538
-
Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC
-
Wang Z, Chen R, Wang S, et al. Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC. PLoS One 2014;9:e110780.
-
(2014)
PLoS One
, vol.9
, pp. e110780
-
-
Wang, Z.1
Chen, R.2
Wang, S.3
-
86
-
-
80053014135
-
A noninvasive system for monitoring resistance to epidermal growth factor receptor tyrosine kinase inhibitors with plasma DNA
-
Nakamura T, Sueoka-Aragane N, Iwanaga K, et al. A noninvasive system for monitoring resistance to epidermal growth factor receptor tyrosine kinase inhibitors with plasma DNA. J Thorac Oncol 2011;6:1639-48.
-
(2011)
J Thorac Oncol
, vol.6
, pp. 1639-1648
-
-
Nakamura, T.1
Sueoka-Aragane, N.2
Iwanaga, K.3
-
87
-
-
84902495614
-
Detection of EGFR mutations in the plasma of patients with lung adenocarcinoma for real-time monitoring of therapeutic response to tyrosine kinase inhibitors?
-
Marcq M, Vallée A, Bizieux A, et al. Detection of EGFR mutations in the plasma of patients with lung adenocarcinoma for real-time monitoring of therapeutic response to tyrosine kinase inhibitors? J Thorac Oncol 2014;9:e49-50.
-
(2014)
J Thorac Oncol
, vol.9
, pp. e49-e50
-
-
Marcq, M.1
Vallée, A.2
Bizieux, A.3
-
88
-
-
84937414146
-
Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor
-
Piotrowska Z, Niederst MJ, Karlovich CA, et al. Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. Cancer Discov 2015;5:713-22.
-
(2015)
Cancer Discov
, vol.5
, pp. 713-722
-
-
Piotrowska, Z.1
Niederst, M.J.2
Karlovich, C.A.3
-
89
-
-
84942159469
-
Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts)
-
Sequist LV, Goldman JW, Wakelee HA, et al. Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol 2015;33:suppl; abstr 8001.
-
(2015)
J Clin Oncol
, vol.33
-
-
Sequist, L.V.1
Goldman, J.W.2
Wakelee, H.A.3
-
90
-
-
84930755018
-
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M
-
Thress KS, Paweletz CP, Felip E, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med 2015;21:560-2.
-
(2015)
Nat Med
, vol.21
, pp. 560-562
-
-
Thress, K.S.1
Paweletz, C.P.2
Felip, E.3
-
91
-
-
79952264325
-
Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations
-
Rosell R, Molina MA, Costa C, et al. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res 2011;17:1160-8.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 1160-1168
-
-
Rosell, R.1
Molina, M.A.2
Costa, C.3
-
92
-
-
84942942154
-
Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non-Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR
-
Watanabe M, Kawaguchi T, Isa S, et al. Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non-Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR. Clin Cancer Res 2015;21:3552-60.
-
(2015)
Clin Cancer Res
, vol.21
, pp. 3552-3560
-
-
Watanabe, M.1
Kawaguchi, T.2
Isa, S.3
|